eliquis apixaban logo eliquis apixaban logo eliquis apixaban logo

This information is intended for healthcare professionals based in the UK.

If you are not a healthcare professional in the UK, please click here.

For Prescribing and Adverse Event reporting information, click here.

desk-img mob-img

AMPLIFY CLINICAL TRIAL

In AMPLIFY, ELIQUIS (apixaban) demonstrated comparable efficacy with significantly fewer major bleeding events vs. enoxaparin / warfarin in patients receiving treatment for DVT / PE1

* Efficacy analyses based on ITT population for whom the outcome status at 6 months was documented. Safety analyses based on patients who had at least one dose of study drug.

Diagnosemethoden

ELIQUIS dosing for your patients with DVT / PE is simple: START twice daily, STAY twice daily3

It’s simple to switch your patients to ELIQUIS3

Dosing could differ for some patients with renal or hepatic impairment3

View information to assist your daily practice, including adverse reactions, contraindications and interactions


ELIQUIS (apixaban) SmPC

Please click here to access the ELIQUIS SmPC.

ELIQUIS (apixaban) Patient Information Leaflet

Please click here to access the ELIQUIS Patient Information Leaflet.

AMPLIFY = Apixaban for the Initial Management of Pulmonary Embolism and Deep Vein Thrombosis as First-Line Therapy   
ARR = Absolute Risk Reduction   
CI = Confidence Interval   
DVT = Deep Vein Thrombosis   
LMWH = Low Molecular Weight Heparin   
N = Total number of patients in either the ELIQUIS group or the enoxaparin / warfarin group   
n = Number of patients with event   
PE = Pulmonary Embolism   
RR = Relative Risk   
RRR = Relative Risk Reduction   
VTE = Venous Thromboembolic Events

‡ In patients with PE (with or without DVT), 21 events were reported in the ELIQUIS group vs. 23 events in the enoxaparin / warfarin group. In patients with DVT only, 38 events were reported in the ELIQUIS group vs. 47 events in the enoxaparin / warfarin group.2

References

  1. Agnelli G et al. N Engl J Med 2013; 369: 799‒808.
  2. Agnelli G et al. N Engl J Med 2013; 369: 799‒808. Supplementary appendix.
  3. ELIQUIS® (apixaban) Summary of Product Characteristics.